Two recent studies from researchers at Washington University School of Medicine in St. Louis have identified a promising way ...

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

Astellas and Daiichi Sankyo’s drugs are being positioned initially as second-generation FLT3 inhibitors that build on the activity seen with Rydapt and extend the use of the class into second ...

If it makes it to market, the drug will compete with Daiichi Sankyo's Turalio (pexidartinib), a CSF1R, KIT, and FLT3 inhibitor that was cleared for TGCT by the FDA in 2019, and potentially Ono's ...

The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

The company’s first drug candidate ... Designed as a next generation FLT3 tyrosine kinase inhibitor, PHI-101 has a novel mechanism of action to overcome resistance to AML.

Biomea Fusion (BMEA) announced preliminary data from the ongoing Phase I COVALENT-103 study evaluating BMF-500, the company’s investigational covalent FLT3 inhibitor developed using the ...

Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active ...

While genomics, transcriptomics, and standard proteomics can provide clues about pathway ... targets the FLT3 receptor (WT and/or mutant), was approved by the US Food and Drug Administration ...

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of ...